glecaprevir: Clinical Trials

10 trials of glecaprevir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed. 10 Phase 2, 6 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 210Completed 10
Phase 36Completed 6
Phase 11Completed 1

Follow glecaprevir: new trials by email Literature Review of glecaprevir trials Research Report on glecaprevir

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Glecaprevir/Pibrentasvir for the Treatment of PTSD
Glecaprevir / Pibrentasvir Pill - PTSD
Phase 2 / Phase 3CompletedWhite River Junction Veterans Affairs Medical Center102023-04-012024-08-29
Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor
glecaprevir/pibrentasvir (GLE/PIB) - Hepatitis C, Hepatitis C Virus Infection, Response to Therapy of
Phase 1 / Phase 2CompletedUniversity of California, San Diego122021-05-282022-05-24
Utilization of Hepatitis C Positive Kidneys in Negative Recipients
Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET] - Kidney Transplant, Hepatitis C
Phase 2 / Phase 3CompletedOhio State University542019-03-222023-09-13
A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret
Mavyret - Hepatitis C
Phase 2CompletedNYU Langone Health202018-05-122021-09-05
A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection
Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation - Hepatitis C Virus (HCV)
Phase 2 / Phase 3CompletedAbbVie1292017-03-202023-05-09
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
ABT-493, ABT-530 - Hepatitis C
Phase 2 / Phase 3CompletedAbbVie3842015-06-222020-09-21
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy
ABT-493, ABT-530, ribavirin (RBV), ABT-493/ABT-530 - Chronic Hepatitis C, Hepatitis C Virus
Phase 2 / Phase 3CompletedAbbVie1412015-04-012017-09-15
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
ABT-493, ABT-530, ribavirin (RBV) - Chronic Hepatitis C, Hepatitis C Virus
Phase 2 / Phase 3CompletedAbbVie6942014-09-192021-07-30
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection
ABT-493, ABT-530 - Chronic Hepatitis C, Hepatitis C Virus
Phase 2CompletedAbbVie1742014-08-012021-07-13
A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)
ABT-493, ABT-530, ABT-450/r/ABT-267, ABT-333 - Chronic Hepatitis C, Hepatitis C Virus
Phase 2CompletedAbbVie892013-11-012021-07-12

Conditions studied

Hepatitis C (10)  ·  Hepatitis C, Chronic (6)  ·  Fibrosis (2)  ·  Stress Disorders, Post-Traumatic (1)

Sponsors

AbbVie (6)  ·  NYU Langone Health (1)  ·  Ohio State University (1)  ·  University of California, San Diego (1)  ·  White River Junction Veterans Affairs Medical Center (1)

Countries

United States (6)  ·  Belgium (2)  ·  Canada (2)  ·  Germany (2)  ·  Puerto Rico (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Japan (1)  ·  New Zealand (1)  ·  Russia (1)  ·  Spain (1)

Top investigators

Armen Asatryan, MD (1)  ·  Bradley V Watts, MD, MPH (1)  ·  Luis Angel, MD (1)  ·  Reem Daloul, MD (1)

Results publications

PMID 30012435, PMID 30923816, PMID 30977945, PMID 31568620, PMID 26711747, PMID 27456384, PMID 28128852, PMID 28412293, PMID 28951228, PMID 30868245, PMID 31254392, PMID 33811356, PMID 35220658, PMID 42189498

NIH funding

2014 (2), 2015 (2), 2016 (1)